Priser
Platform
Blog
Om os
Download
ScinoPharm Taiwan
ScinoPharm Taiwan
Taiwan Stock Exchange
0

Om

Scinopharm Taiwan Ltd. operates as a specialized pharmaceutical company that focuses on the research, development, and manufacture of active pharmaceutical ingredients (APIs). Known for its strong emphasis on technological innovation and quality control, Scinopharm serves as a crucial entity in the global pharmaceutical supply chain. The company's product portfolio spans a variety of therapeutic categories, including oncology, central nervous system disorders, and cardiovascular diseases. Scinopharm's facilities adhere to international regulatory standards, ensuring the production of APIs that meet stringent quality criteria for both generic and branded pharmaceuticals. With strategic locations in Taiwan and China, the company efficiently caters to the demands of pharmaceutical manufacturers worldwide. Scinopharm's commitment to advanced manufacturing processes and collaborative development projects positions it as a leader in the pharmaceutical manufacturing industry, contributing significantly to enhancing drug availability and accessibility across global healthcare markets.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SCINOPHARM TAIWAN MED ENDAVU: Køb ScinoPharm Taiwan ($1789) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i ScinoPharm Taiwan, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker1789
Land
Taiwan
Hjemmesidescinopharm.com
SektorSundhed
IndustriLægemiddelproducenter - Specialitet og generisk

Udbytter

0,27TWD
'20
0,5TWD
'21
0,48TWD
'22
0,36TWD
'23
0,3TWD
'24
0,35TWD
'25
Ex-udbytte-dato3. jul. 2025
Udbytteafkast1,75%